Pfizer's Chief Scientific Officer Mikael Dolsten to Step Down After 15 Years, External Search Underway

Jul 9, 2024, 11:50 AM

Pfizer announced that its Chief Scientific Officer and President of Global Research & Development, Dr. Mikael Dolsten, will step down after a more than 15-year tenure at the company. Dolsten, a key figure behind the development of Pfizer's COVID-19 vaccine, joined Pfizer in 2009 following the Wyeth acquisition, where he served as president and head of R&D. Prior to Wyeth, he held significant roles at Boehringer and AstraZeneca. Pfizer has initiated an external search for Dolsten's successor, with Dolsten remaining part of the interview team and staying through the transition. This move comes as Pfizer's C-suite undergoes multiple changes post-pandemic and amid the integration of the $43 billion Seagen merger.